Table 6.

Overexpression of a Constitutively Activated AKT1 Renders HL-60 PT Cells Resistant to Apoptosis Inducers and ATRA, Whereas Overexpression of a Dominant Negative AKT1 Restores Sensitivity of HL-60 AR Cells to Drugs and ATRA

TreatmentPT CellsTransfected PT Cells
AR CellsTransfected AR Cells
12FC17GC18M2W3G3Y
None (control)5.3 ± 1.53.7 ± 2.33.1 ± 1.82.9 ± 2.31.5 ± 2.05.5 ± 2.14.9 ± 2.45.7 ± 2.6
Camptothecin (0.1 μg/ml)77.3 ± 8.94.5 ± 2.55.0 ± 2.84.7 ± 1.84.8 ± 2.159.5 ± 6.863.4 ± 7.062.3 ± 7.4
Etoposide (5 μg/ml)68.2 ± 7.84.8 ± 1.94.3 ± 1.64.9 ± 1.94.6 ± 1.837.7 ± 4.141.2 ± 4.443.5 ± 4.3
Doxorubicin (100 μg/ml)46.6 ± 6.15.0 ± 3.85.9 ± 2.24.7 ± 2.15.6 ± 2.325.4 ± 3.124.9 ± 3.623.6 ± 3.3
Cytarabine (40 μg/ml)59.4 ± 5.66.5 ± 2.46.7 ± 3.05.4 ± 2.65.2 ± 1.740.8 ± 4.642.1 ± 5.044.5 ± 5.1
Mitoxantrone (40 μg/ml)51.5 ± 6.65.5 ± 2.56.0 ± 2.55.6 ± 2.94.7 ± 2.628.3 ± 3.629.5 ± 4.026.6 ± 3.7
Vincristine (4 μg/ml)54.4 ± 6.04.9 ± 2.65.7 ± 2.24.9 ± 2.74.4 ± 3.032.2 ± 3.732.8 ± 3.430.3 ± 2.9
ATRA79.6 ± 8.07.3 ± 3.16.9 ± 3.16.6 ± 3.47.1 ± 1.475.9 ± 7.372.3 ± 8.178.7 ± 8.8
  • Note: The results show the percentage of apoptotic (in the case of drugs) or differentiated (in the case of ATRA) cells. Cells were exposed to the drugs for 24 h or to ATRA for 4 days. Data are the means ± SD from three separate experiments.